Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2022 | Bone marrow as a superior source of stem cells after PTCy-based haplo-HSCT

Vanderson Rocha • 28 Oct 2022
COSTEM 2022
General Cyclophosphamide

Vanderson Rocha, MD, Fundação Pró-Sangue Hemocentro de São Paulo & Universidade de São Paulo, Sao Paulo, Brazil, discusses findings from a meta-analysis comparing peripheral blood versus bone marrow as a source of stem cells after haploidentical hematopoietic stem cell transplantation (HSCT) with post-transplant cyclophosphamide (PTCy). Using bone marrow reduced rates of mortality and graft-versus-host disease (GvHD). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Vanderson Rocha

1:17
The benefits and drawbacks of cord blood transplantation
Vanderson Rocha • 28 Oct 2022
1:29
The state of stem cell transplantation for multiple myeloma in Brazil
Vanderson Rocha • 28 Oct 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals